Equities

Pure Biologics SA

Pure Biologics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)22.00
  • Today's Change1.10 / 5.26%
  • Shares traded131.90k
  • 1 Year change+64.18%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of PLN
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3.617.1833
Total Receivables, Net15159.29
Total Inventory------
Prepaid expenses------
Other current assets, total0.421.780.80
Total current assets192443
Property, plant & equipment, net0.888.423.45
Goodwill, net------
Intangibles, net0.260.400.71
Long term investments00.020.02
Note receivable - long term------
Other long term assets------
Total assets233347
LIABILITIES
Accounts payable1.037.240.67
Accrued expenses5.173.373.74
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.091.101.11
Other current liabilities, total0.931.140.02
Total current liabilities7.21135.55
Total long term debt131.772.00
Total debt132.863.11
Deferred income tax------
Minority interest------
Other liabilities, total0.790.110.16
Total liabilities21157.70
SHAREHOLDERS EQUITY
Common stock0.330.230.23
Additional paid-in capital------
Retained earnings (accumulated deficit)1.561839
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total--0.00--
Total equity1.891839
Total liabilities & shareholders' equity233347
Total common shares outstanding3.332.252.25
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.